Equibles does not estimate personal net worth.
Get an email with a short summary when X4 Pharmaceuticals, Inc publishes a filing, an earnings call transcript or a press release.
Get XFOR alertsPaula Ragan is recorded as CEO at X4 Pharmaceuticals, Inc (XFOR). The newest filing on record that lists Paula Ragan as CEO at X4 Pharmaceuticals, Inc (XFOR) is dated April 25, 2025. X4 Pharmaceuticals, Inc reported in an 8-K filed August 12, 2025 that Paula Ragan resigned as Board of Directors. The proxy statement of X4 Pharmaceuticals, Inc reports total compensation of $2,640,569 for Paula Ragan in fiscal 2025, including a base salary of $420,170. Disclosed compensation is on record for 8 fiscal years. Paula Ragan has spoken on 19 earnings calls across 1 company, most recently for X4 Pharmaceuticals, Inc on May 1, 2025. X4 Pharmaceuticals, Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at X4 Pharmaceuticals, Inc includes Adam Raymond Craig, M.D., Ph.D. (CEO, Chairman and Board Member), Michael Gray (CEO), Adam Craig (Chairman) and 7 others.
“Dr. Ragan has also resigned from the Board of Directors, and Michael Wyzga has transitioned from Board Chair to Lead Independent Director.”
“The first quarter of 2025 was an extremely productive and value-building period for X4 with clinical trial advancement in chronic neutropenia, continued progress in the commercialization of XOLREMDI for WHIM syndrome in the US and our achievement of several significant milestones towards expanding the global potential…”
“Today, we will provide an update on our operational achievements, including activities supporting the launch of XOLREMDI in the U.S. and the substantial progress to date with our ongoing Phase III clinical trial of mavorixafor in people with chronic neutropenia or CN.”
“Following last week's approval of XOLREMDI, it's exciting to reiterate today why this critical regulatory achievement represents a significant opportunity to improve the lives of WHIM patients and offers a strong platform for the company's growth.”
“As we look ahead to 2024, we thought we’d take the time to reflect on all that we’ve accomplished over the past year, milestones that have set the stage for what we expect will be an incredibly exciting and truly transformative year for X4, a year where we aim to become a fully integrated research, development and…”
“To start, I’ll be reviewing our third quarter events and recent highlights, the first two of which will be the primary focus of our discussion today.”
Start not stated–present
Last confirmed April 25, 2025
Start not stated–2025-08-12
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | X4 Pharmaceuticals, Inc (XFOR) | Former President and Chief Executive Officer | $420,170 | $2,640,569 |
| 2024 | X4 Pharmaceuticals, Inc (XFOR) | President and Chief Executive Officer | $654,156 | $2,145,041 |
| 2023 | X4 Pharmaceuticals, Inc (XFOR) | President and Chief Executive Officer | $620,053 | $2,044,761 |
| 2022 | X4 Pharmaceuticals, Inc (XFOR) | President and Chief Executive Officer | $583,481 | $3,872,533 |
| 2021 | X4 Pharmaceuticals, Inc (XFOR) | President and Chief Executive Officer | $562,126 | $2,141,328 |
| 2020 | X4 Pharmaceuticals, Inc (XFOR) | President and Chief Executive Officer | $543,400 | $2,513,532 |
| 2019 | X4 Pharmaceuticals, Inc (XFOR) | President, Chief Executive Officer, Corporate Secretary and Director | $492,276 | $2,497,851 |
| 2018 | X4 Pharmaceuticals, Inc (XFOR) | President, Chief Executive Officer, Corporate Secretary and Director | $380,000 | $921,027 |
